Hydralazine therapy in hypertensive patients with idiopathic systemic lupus erythematosus
| Autor: | Leslie Dornfeld, Michael J. Reza, Leonard S. Goldberg |
|---|---|
| Rok vydání: | 1975 |
| Předmět: |
Adult
Male medicine.medical_specialty Anti-nuclear antibody Exacerbation Neutrophils Immunology Azathioprine Gastroenterology Rheumatology Prednisone Internal medicine medicine Humans Lupus Erythematosus Systemic Immunology and Allergy Pharmacology (medical) skin and connective tissue diseases Systemic lupus business.industry Complement System Proteins Middle Aged Hydralazine Antibodies Antinuclear Concomitant Hypertension Female business medicine.drug |
| Zdroj: | Arthritis & Rheumatism. 18:335-338 |
| ISSN: | 1529-0131 0004-3591 |
| DOI: | 10.1002/art.1780180407 |
| Popis: | Seven hypertensive patients with idiopathic systemic lupus erythematosus were treated with hydralazine. They received a mean daily dose of 203 mg for a mean duration of 21 months. All were taking prednisone alone or in combination with azathioprine. During therapy with hydralazine, there were no new symptoms nor exacerbation of pre-existing symptoms attributable to systemic lupus. Laboratory parameters, including antinuclear antibody titers and complement levels, either improved or remained stable. The results indicate that hydralazine can be safely used in hypertensive patients with systemic lupus who are receiving concomitant immunosuppressive therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text